RU98101249A - OMR26 ANTIGEN HAEMOPHYLUS INFLUENZAE - Google Patents

OMR26 ANTIGEN HAEMOPHYLUS INFLUENZAE

Info

Publication number
RU98101249A
RU98101249A RU98101249/13A RU98101249A RU98101249A RU 98101249 A RU98101249 A RU 98101249A RU 98101249/13 A RU98101249/13 A RU 98101249/13A RU 98101249 A RU98101249 A RU 98101249A RU 98101249 A RU98101249 A RU 98101249A
Authority
RU
Russia
Prior art keywords
protein
vaccine
amino acid
influenzae
paragraphs
Prior art date
Application number
RU98101249/13A
Other languages
Russian (ru)
Other versions
RU2221045C2 (en
Inventor
Кид Дженнелле
Криппс Аллан
Джон Смит Кристофер
Original Assignee
Кортекс Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513074.6A external-priority patent/GB9513074D0/en
Application filed by Кортекс Интернэшнл Лимитед filed Critical Кортекс Интернэшнл Лимитед
Publication of RU98101249A publication Critical patent/RU98101249A/en
Application granted granted Critical
Publication of RU2221045C2 publication Critical patent/RU2221045C2/en

Links

Claims (12)

1. Вакцинное средство, включающее белок, имеющий молекулярный вес 26 кДа, определенный с помощью ПААГЭ с ДСН, причем белок представляет собой белок внешней мембраны Н. influenzae, необязательно вместе с одним или более носителей и/или адъювантов.1. A vaccine product comprising a protein having a molecular weight of 26 kDa, determined by SDSAGE with SDS, the protein being a protein of the outer membrane of H. influenzae, optionally together with one or more carriers and / or adjuvants. 2. Вакцинное средство по п.1, в котором белок имеет последовательность аминокислот, показанную на фигуре 1, или последовательность по существу гомологичную ей. 2. The vaccine according to claim 1, in which the protein has the amino acid sequence shown in figure 1, or a sequence essentially homologous to it. 3. Вакцинное средство по п.1, в котором белок имеет последовательность аминокислот, показанную на фигуре 1, начиная с двадцать четвертой аминокислоты в качестве N - концевой аминокислоты, или последовательность, по существу гомологичную ей. 3. The vaccine according to claim 1, in which the protein has the amino acid sequence shown in figure 1, starting with the twenty-fourth amino acid as the N-terminal amino acid, or a sequence essentially homologous to it. 4. Вакцинное средство по п.2 или 3, в котором белок имеет последовательность аминокислот, по меньшей мере на 70% гомологичную последовательности аминокислот, показанной на фигуре 1. 4. The vaccine agent according to claim 2 or 3, in which the protein has an amino acid sequence of at least 70% homologous to the amino acid sequence shown in figure 1. 5. Вакцинное средство, включающее белок или пептид, который имеет антигенную часть или район белка, по любому одному из пп. 1 - 4. 5. A vaccine agent comprising a protein or peptide that has an antigenic portion or region of a protein, according to any one of claims. fourteen. 6. Вакцинное средство, включающее в себя белок, который содержит антигенную часть или район белка, по любому одному из пп. 1 - 4. 6. A vaccine product comprising a protein that contains an antigenic portion or region of a protein, according to any one of paragraphs. fourteen. 7. Вакцинное средство по п.6, в которой белок является слитым белком. 7. The vaccine according to claim 6, in which the protein is a fusion protein. 8. Применение белка, по любому одному из пп. 1 - 7 для приготовления вакцины против Н. influenzae. 8. The use of protein, according to any one of paragraphs. 1 to 7 for the preparation of a vaccine against H. influenzae. 9. Способ иммунизации субъекта против инфекции, вызываемой Н. influenzae, который включает в себя введение субъекту вакцинного средства по любому одному из пп. 1 - 7. 9. A method of immunizing a subject against an infection caused by H. influenzae, which comprises administering to the subject a vaccine according to any one of claims. 1 - 7. 10. Способ профилактики или лечения инфекций респираторного тракта или воспаления среднего уха, который включает в себя стадию введения субъекту вакцинного средства по любому одному из пп. 1 - 7. 10. A method for the prevention or treatment of respiratory tract infections or middle ear inflammation, which includes the step of administering to the subject a vaccine according to any one of claims. 1 - 7. 11. Применение белка, по любому одному из пп. 1 - 7 в диагностике инфекции Н. influenzae. 11. The use of protein, according to any one of paragraphs. 1 - 7 in the diagnosis of H. influenzae infection. 12. Набор реактивов (кит) для применения в диагностике инфекции Н. influenzae, включающий белок, по любому одному из пп. 1 - 7. 12. A set of reagents (whale) for use in the diagnosis of H. influenzae infection, including protein, according to any one of paragraphs. 1 - 7.
RU98101249/13A 1995-06-27 1996-06-27 Haemophilus influenzae antigen omp26, nucleic acid encoding it and its using RU2221045C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513074.6A GB9513074D0 (en) 1995-06-27 1995-06-27 Novel anigen
GB9513074.6 1995-06-27

Publications (2)

Publication Number Publication Date
RU98101249A true RU98101249A (en) 1999-12-10
RU2221045C2 RU2221045C2 (en) 2004-01-10

Family

ID=10776746

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98101249/13A RU2221045C2 (en) 1995-06-27 1996-06-27 Haemophilus influenzae antigen omp26, nucleic acid encoding it and its using

Country Status (18)

Country Link
US (4) US6245338B1 (en)
EP (1) EP0835313B1 (en)
JP (2) JPH11510373A (en)
KR (1) KR19990028423A (en)
CN (1) CN1144875C (en)
AT (1) ATE317013T1 (en)
AU (1) AU708061B2 (en)
CA (1) CA2225405A1 (en)
DE (1) DE69635783T2 (en)
ES (1) ES2259443T3 (en)
GB (1) GB9513074D0 (en)
MX (1) MX9710412A (en)
NO (1) NO976119L (en)
NZ (1) NZ311120A (en)
RU (1) RU2221045C2 (en)
TW (1) TW457247B (en)
WO (1) WO1997001638A1 (en)
ZA (1) ZA965482B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US6468765B1 (en) 1995-04-21 2002-10-22 Human Genome Sciences, Inc. Selected Haemophilus influenzae Rd polynucleotides and polypeptides
GB9904183D0 (en) * 1999-02-24 1999-04-14 Smithkline Beecham Biolog Novel compounds
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
DK2270171T5 (en) * 2000-10-02 2013-11-18 Id Biomedical Corp Quebec Haemophilus influenzae antigens and corresponding DNA fragments
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
US20100034822A1 (en) * 2005-03-30 2010-02-11 Vega Masignani Haemophilus Influenzae Type B
CN100357318C (en) * 2005-10-11 2007-12-26 中山大学 Mermaid photobacterium envelop protein W and coding sequence , its preparation method and uses
KR100743604B1 (en) * 2005-12-05 2007-07-27 볼보 컨스트럭션 이키프먼트 홀딩 스웨덴 에이비 muffler structure for vehicle
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
LT3017827T (en) 2005-12-22 2019-01-10 Glaxosmithkline Biologicals S.A. Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
ZA200805602B (en) 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
KR20100045445A (en) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013521770A (en) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine composition
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
CA2838188C (en) 2011-06-04 2017-04-18 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
CA2871520C (en) * 2012-04-26 2020-12-29 Novartis Ag Antigens from non-typeable h. influenzae
CN104370997B (en) * 2014-09-24 2018-07-31 陈辉 Remove kit, the preparation method of method and its biological products of bacterial endotoxin in biological products
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
JP7291633B2 (en) 2017-05-30 2023-06-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Method for manufacturing an adjuvant
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
MX2021001479A (en) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Processes and vaccines.
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100188323B1 (en) * 1989-03-09 1999-06-01 이곤 이이 버어그 Vaccines for nontypable haemophilus influenzae
GB9224584D0 (en) * 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases

Similar Documents

Publication Publication Date Title
RU98101249A (en) OMR26 ANTIGEN HAEMOPHYLUS INFLUENZAE
RU2221045C2 (en) Haemophilus influenzae antigen omp26, nucleic acid encoding it and its using
Lowell et al. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides
Martin et al. Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis
CA1340956C (en) Synthetic peptides representing a t-cell epitope as a carrier molecule for conjugate vaccines
JP3240063B2 (en) Actinobacillus subunit vaccine for swine lung disease
RU2000116260A (en) LTB ADJUVANT VACCINES
CA2223013C (en) Methods of raising antibodies against e.coli of the family cs4-cfa/1
WO1989002277A3 (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
KR970703164A (en) Treatment and Prevention of Helicobacter Infection (TREATMENT AND PREVENTION OF HELICOBACTER INFECTION)
JP2003520765A (en) Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis by Porphyromonas gingivalis
US7144580B2 (en) M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever
FI120149B (en) Purified P5 protein of non-typable Haemophilus influenzae as vaccine against a non-typable Haemophilus influenzae strain
CA2337754A1 (en) Recombinant multivalent malarial vaccine against plasmodium falciparum
JPH11509200A (en) Clostridium difficile toxin as a mucosal adjuvant
WO2002092131A3 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
HUP9904171A2 (en) Immunogenic peptides of foot-and-mouth disease viruses
ATE82687T1 (en) PREPARATIONS EFFECTIVE AGAINST PSEUDOMONAS AERUGINOSA INFECTION AND PROCESS FOR THEIR PREPARATION.
JPH0840927A (en) Method for dosing pneumococcal antigen per mucosa
US4695562A (en) Synthetic peptide compounds
Tsurumi et al. Production of antibody against a synthetic peptide of Porphyromonas gingivalis 40-kDa outer membrane protein
JP2000502987A (en) Oral administration of pneumococcal antigen
FR2809960A1 (en) Preparing an immunological adjuvant composition or an immunostimulant composition, for use in e.g. in vaccines containing bacterial, viral or parasitic antigens, comprises using filamentous hemagglutinin protein
Beachey Protective immunity evoked by synthetic peptides of streptococcal M proteins
WO1996039113A3 (en) Oral administration of pneumococcal antigens